Veravas launched in 2017 with a mission that went far beyond just selling technology or building products. We want to impact healthcare, raising the bar for diagnostic accuracy, efficacy, and the scope of what can be tested. Below are some milestones and inflection points in this journey.
Veravas, Inc., an emerging diagnostic company, today announced the appointment of Carroll E. Streetman Jr., as chief executive officer. Mr. Streetman brings over 45 years of experience in highly relevant healthcare industry experience to the position.
Medical Laboratory Observer shared news of the launch of the Veravas biotin interference product portfolio, including VeraTest Biotin, VeraPrep Biotin and VeraBind Biotin.
Veravas, Inc. is showcasing for the first time, a newly launched portfolio of laboratory products to detect and manage biotin interference at the American Association for Clinical Chemistry (AACC) annual meeting on August 4-8, 2019 in Anaheim, California.
Register to receive updates and more information as it becomes available – from product launches to conference posters to novel partnerships and events.